Watch NRIX. Know when insiders buy.
One email the day a filing lands. Free.
NRIX
Nurix Therapeutics, Inc.
26.10
+1.17 +4.69%
USD · Oct 20, 07:40 p.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
38
FLAG · insiders 26, shorts 50
Insiders, 90 days
−$885K
net selling · 0 buys, 6 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.9BP/E 11.3DIV YIELD —FCF YIELD 12.97%REV TTM $701.9M +738.8%NET INCOME $294.9MNET CASH —52W 10.40 – 27.79SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Aug 31 | $673.1M | +8426.3% | — | $559.5M | $549.8M | — | 4.73 | $615.6M | $1.4M | $614.2M | Oct 13 |
| Q2 2026 · May 31 | $9M | −79.5% | — | −$94.2M | −$89.5M | — | -0.81 | −$96.6M | $1.9M | −$98.5M | Oct 13 |
| Q1 2026 · Feb 28 | $6.3M | −66.1% | — | −$92.5M | −$87.2M | — | -0.79 | −$71.9M | $1M | −$73M | Oct 13 |
| Q4 2025 · Nov 30derived | $13.6M | +2.2% | — | −$83.1M | −$78.2M | — | -0.83 | −$67.8M | $5.1M | −$73M | Jan 28 |
| Q3 2025 · Aug 31 | $7.9M | −37.3% | — | −$91.4M | −$86.4M | — | -1.03 | −$57.4M | $2.7M | −$60.1M | Oct 13 |
| Q2 2025 · May 31 | $44.1M | +264.3% | — | −$48.3M | −$43.5M | — | -0.52 | −$63.2M | $2.7M | −$65.8M | Oct 13 |
| Q1 2025 · Feb 28 | $18.5M | +11.3% | — | −$62.9M | −$56.4M | — | -0.67 | −$61.1M | $3.5M | −$64.6M | Oct 13 |
| Q4 2024 · Nov 30derived | $13.3M | −12.4% | — | −$64.7M | −$58.5M | — | -0.75 | −$48.8M | $2.1M | −$50.9M | Jan 28 |
| Q3 2024 · Aug 31 | $12.6M | — | — | −$54.6M | −$49M | — | -0.67 | −$42.2M | $2.3M | −$44.5M | Oct 9 |
| Q2 2024 · May 31 | $12.1M | — | — | −$48.5M | −$44.5M | — | -0.71 | −$39.7M | $1.9M | −$41.6M | Oct 9 |
| Q1 2024 · Feb 29 | $16.6M | — | — | −$45.2M | −$41.5M | — | -0.76 | −$42M | $2.9M | −$44.8M | Oct 9 |
| Q4 2023 · Nov 30derived | $15.2M | — | — | −$45.3M | −$42M | — | -0.77 | $26.7M | $2.6M | $24.1M | Jan 28 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Nov 30 | $84M | — | −$285.7M | −$264.5M | -314.9% | -3.05 | −$249.5M | $14M | −$263.5M | — | — |
| FY2024 · to Nov 30 | $54.5M | — | −$213M | −$193.6M | -354.9% | -2.88 | −$172.6M | $9.3M | −$181.9M | — | — |
| FY2023 · to Nov 30 | $77M | — | −$155.1M | −$143.9M | -187.0% | -2.65 | −$81.4M | $8.4M | −$89.8M | — | — |
| FY2022 · to Nov 30 | $38.6M | — | −$183.9M | −$180.4M | -466.9% | -3.71 | −$159.8M | $12.2M | −$172.1M | — | — |
| FY2021 · to Nov 30 | $29.8M | — | −$117.9M | −$117.2M | -393.9% | -2.73 | −$84.4M | $5.7M | −$90M | — | — |
| FY2020 · to Nov 30 | $17.8M | — | −$65M | −$43.2M | -242.7% | -2.76 | −$80K | $4.6M | −$4.6M | — | — |
Every number comes from Nurix Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.